AEOL 10150 / Aeolus - LARVOL DELTA

Aeolus Announces $6.75 Million Private Placement Financing (Yahoo Finance) - "Aeolus Pharmaceuticals, Inc...announced today that it has entered into definitive agreements with certain institutional and other accredited investors to raise gross proceeds of $6.75 million in a private placement financing....In addition, the Company intends to use the proceeds to pursue human clinical trials with AEOL 10150 in Idiopathic Pulmonary Fibrosis and radiation oncology and the completion of pre-clinical development of AEOL 20415 for infectious diseases and AEOL 11114B for Parkinson's disease."

Financing • CNS Disorders • Idiopathic Pulmonary Fibrosis • Parkinson's Disease • Pulmonary Disease

Novel Catalytic Antioxidant Formulations Decrease Oxidative Stress, Neuroinflammation and Cognitive Dysfunction in Diisopropylflurophoshate-Induced Status Epilepticus (AES 2023) - "We have previously demonstrated the efficacy of a water-for-injection formulation of the meso-porphyrin catalytic antioxidant, AEOL10150 against oxidative stress, neuroinflammation, and neuronal death initiated by kainic acid, pilocarpine, diisopropylflurophoshate (DFP) and soman. These results suggest that reformulation of AEOL10150 can attenuate acute and delayed outcomes of organophosphate neurotoxicity."

Oxidative stress • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Inflammation

Novel Catalytic Antioxidant Formulations Decrease Oxidative Stress, Neuroinflammation and Cognitive Dysfunction in a model of Nerve Agent Intoxication. (PubMed, J Pharmacol Exp Ther) - "We have previously demonstrated the efficacy of a water-for-injection formulation of the meso-porphyrin catalytic antioxidant, AEOL10150 against oxidative stress, neuroinflammation, and neuronal death initiated by kainic acid, pilocarpine, diisopropylflurophosphate (DFP) and soman. Significance Statement Reformulation of AEOL10150 allowed higher tolerated doses of the compound with improved pharmacodynamics. Specifically, one new formulation allowed fewer daily doses and improvement in acute and delayed outcomes of organophosphate toxicity."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Inflammation

AEOL 10150 Alleviates Radiation-induced Innate Immune Responses in Non-human Primate Lung Tissue. (PubMed, Health Phys) - "Cytokine/chemokine-induced excessive innate immune response after thoracic irradiation plays an important role in RILI. To our knowledge, this is the first study to highlight the role of cytokine/chemokine-induced innate immune responses in radiation-induced pulmonary toxicity in a NHP model."

Journal • Respiratory Diseases • CASP3 • CCL11 • CCL2 • CDKN1A • CXCL8 • FN1 • ICAM1 • MDM2 • PTEN

Reduction of peroxynitrite by some manganoporphyrins of AEOL series: DFT approach with dispersion correction and NBO analysis. (PubMed, J Inorg Biochem) - "Reductive oxygen atom cleavage from peroxynitrite (ONOO) to form NO in aqueous solution by some AEOL compounds (AEOL-10113, AEOL-10150, AEOL-11114 and AEOL-11203) was studied by DFT/M06-2X computations with D3 dispersion correction and gCP (geometrical counterpoise correction) for basis set superposition error. In AEOL compounds and their association complexes with ONOO, Mn atom prefered the high spin state (S = 2) to the intermediate spin state (S = 1). Natural bond orbital analysis showed that electron transfer from the most negative oxygen atom in ONOO to Mn atom in MnP has the biggest interaction energy among all kinds of donor-acceptor interactions between ONOO and MnP."

Journal

May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? (PubMed, Antioxidants (Basel)) - P2 | "The MnSOD mimetics of the so-called porphyrin type (e.g., AEOL 10150), salen type (e.g., EUK-8) and cyclic polyamine type (e.g., M40419, today known as GC4419 and avasopasem manganese) have all been shown to positively affect the inflammatory response in lung epithelial cells in preclinical models of chronic obstructive pulmonary disease. announced the dosing of the first patient in a randomized, double-blind pilot phase II clinical trial with GC4419 for COVID-19. The study was first posted on ClinicalTrials.gov (Identifier: NCT04555096) 18 September 2020."

Clinical • Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis • MRI

Identifying Circulating and Lung Tissue Cytokines Associated with Thoracic Irradiation and AEOL 10150 Treatment in a Nonhuman Primate Model. (PubMed, Radiat Res) - "Statistical analysis indicated that circulating cytokines could be discriminatory predictors of AEOL 10150 treatment. Taken together, our data suggested that the cytokine profiles were significantly changed after WTLI as well as mitigator treatment, and that the plasma cytokine profiles could potentially be used to distinguish vehicle or mitigator treatment after WTLI in a NHP model."

Journal • Respiratory Diseases • IL12A • IL15 • IL17A • IL2 • IL6 • IL7

Emergency management of chlorine gas exposure - a systematic review. (PubMed, Clin Toxicol (Phila)) - "Various therapies seem promising based on animal studies or case reports. However, these recommendations are based on low-level quality data. A systematic list of outcomes to monitor and improve may help to design optimal therapeutic protocols to manage chlorine-exposed patients."

Journal • Review